Literature DB >> 26201925

Antioxidant status and GST gene polymorphisms in antitubercular treatment-induced hepatotoxicity patients.

S V Rana1,2, J K Kamboj3, S K Sharma4, R P Ola5, S K Sinha6, K Singh7.   

Abstract

INTRODUCTION: Hepatotoxicity is a serious adverse effect of antituberculosis treatment (ATT). Glutathione S-transferase (GST) is involved in the detoxification of toxic metabolites produced as a result of ATT, increased oxidative stress and decreased antioxidant levels, and differences in the GST polymorphism may be one of the causes of ATT-induced hepatotoxicity. AIM: This study was undertaken to study the relationship among antioxidant status, oxidative stress and GST gene polymorphisms in the development of ATT-induced hepatotoxicity in Indian patients.
METHODOLOGY: Two hundred fifty TB patients attending clinics in the Gastroenterology and Thoracic Department, PGIMER, Chandigarh, were enrolled. Liver marker enzymes, markers of oxidative stress, levels of antioxidants and identification of GSTT1, GSTM1 and GSTP polymorphisms were performed using standard protocols.
RESULTS: Of the 250 patients, 160 were males. Of the 160 males, 18 (11.3 %) had ATT-induced hepatotoxicity and 142 no hepatotoxicity, while of 90 females, 12 (13.3 %) had hepatotoxicity and 78 no hepatotoxicity. Patients who developed ATT-induced hepatotoxicity had significantly higher oxidative stress compared to those who did not develop hepatotoxicity at between 1 and 2 months of treatment. Among antioxidants, catalase did not show any significant difference at 2 and 4 months of treatment. The presence of GSTM1 was higher in hepatotoxicity patients as compared to non-hepatotoxicity patients, while GSTT1 and GST1/M1 were lower.
CONCLUSION: Therefore, in this study, the possible association of oxidative stress with ATT-induced hepatotoxicity was observed. A role of the GST polymorphism in ATT-induced hepatotoxicity was also found and thus could possibly identify the groups at highest risk of developing ATT-induced hepatotoxicity.

Entities:  

Keywords:  Glutathione S-transferase; Hepatotoxicity; Isoniazid; Oxidative stress

Year:  2013        PMID: 26201925     DOI: 10.1007/s12072-013-9452-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  29 in total

1.  Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.

Authors:  Raquel Lima de Figueiredo Teixeira; Renata Gomes Morato; Pedro Hernan Cabello; Ligia Mayumi Kitada Muniz; Adriana da Silva Rezende Moreira; Afrânio Lineu Kritski; Fernanda Carvalho Queiroz Mello; Philip Noel Suffys; Antonio Basilio de Miranda; Adalberto Rezende Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-09       Impact factor: 2.743

2.  Induction of oxidative stress in antitubercular drug-induced hepatotoxicity.

Authors:  A Chowdhury; A Santra; S Kundu; A Mukherjee; A Pandit; S Chaudhuri; G K Dhali
Journal:  Indian J Gastroenterol       Date:  2001 May-Jun

3.  Isoniazid hepatitis.

Authors:  W C Maddrey; J K Boitnott
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

4.  A methodology for analysis of tissue sulfhydryl components.

Authors:  A F Boyne; G L Ellman
Journal:  Anal Biochem       Date:  1972-04       Impact factor: 3.365

5.  Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.

Authors:  Yi-Shin Huang; Wei-Juin Su; Yi-Hsiang Huang; Chih-Yen Chen; Full-Young Chang; Han-Chieh Lin; Shou-Dong Lee
Journal:  J Hepatol       Date:  2007-03-06       Impact factor: 25.083

6.  Monitoring and management of antituberculosis drug induced hepatotoxicity.

Authors:  Subhash Agal; Rajiv Baijal; Snehanshu Pramanik; Nikhil Patel; Parijat Gupte; Praful Kamani; Deepak Amarapurkar
Journal:  J Gastroenterol Hepatol       Date:  2005-11       Impact factor: 4.029

7.  GSTM1 null polymorphism at the glutathione S-transferase M1 locus: phenotype and genotype studies in patients with primary biliary cirrhosis.

Authors:  M H Davies; E Elias; S Acharya; W Cotton; G C Faulder; A A Fryer; R C Strange
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

8.  Theta, a new class of glutathione transferases purified from rat and man.

Authors:  D J Meyer; B Coles; S E Pemble; K S Gilmore; G M Fraser; B Ketterer
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

9.  Characterization and chromosome location of the gene GSTZ1 encoding the human Zeta class glutathione transferase and maleylacetoacetate isomerase.

Authors:  A C Blackburn; E Woollatt; G R Sutherland; P G Board
Journal:  Cytogenet Cell Genet       Date:  1998

10.  The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer.

Authors:  B Ketterer; J M Harris; G Talaska; D J Meyer; S E Pemble; J B Taylor; N P Lang; F F Kadlubar
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

View more
  3 in total

1.  Genetic profiles to identify talents in elite endurance athletes and professional football players.

Authors:  David Varillas-Delgado; Esther Morencos; Jorge Gutiérrez-Hellín; Millán Aguilar-Navarro; Alejandro Muñoz; Nuria Mendoza Láiz; Teresa Perucho; Antonio Maestro; Juan José Tellería-Orriols
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

2.  Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.

Authors:  Eun Kyoung Chung; Jangik I Lee; Seungwon Yang; Se Jung Hwang; Jung Yun Park
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

3.  Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study.

Authors:  David Varillas Delgado; Juan José Tellería Orriols; Carlos Martín Saborido
Journal:  Sports Med Open       Date:  2019-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.